<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00743652</url>
  </required_header>
  <id_info>
    <org_study_id>6096A1-3010</org_study_id>
    <secondary_id>B1851009</secondary_id>
    <nct_id>NCT00743652</nct_id>
  </id_info>
  <brief_title>Study Evaluating the Impact of the 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Alaskan Native Children.</brief_title>
  <official_title>A Phase 3, Open Label Trial Evaluating the Safety, Immunogenicity and Impact of 13-valent Pneumococcal Conjugate Vaccine in Alaskan Native Children.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to evaluate the safety, immunogenicity and impact of 13-valent Pneumococcal
      conjugate vaccine in Alaskan Native Children.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 Micrograms Per Milliliter (Mcg/mL) 1 Month After the Infant Series</measure>
    <time_frame>28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.</time_frame>
    <description>Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Toddler Dose</measure>
    <time_frame>28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.</time_frame>
    <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Relevant Catch-Up Dose</measure>
    <time_frame>28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.</time_frame>
    <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Serum IgG Antibody Level ≥0.35 Mcg/mL Prior to Vaccination With 13vPnC (Groups 4 and 5 Only)</measure>
    <time_frame>28 to 56 days before vaccination 2 for Group 4, and before the single vaccination in Group 5.</time_frame>
    <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Infant Series</measure>
    <time_frame>28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.</time_frame>
    <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Toddler Dose</measure>
    <time_frame>28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.</time_frame>
    <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Relevant Catch-up Dose</measure>
    <time_frame>28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.</time_frame>
    <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 1</measure>
    <time_frame>Day 1 through Day 7 after vaccination 1 for Group 4 and after the single vaccination in Group 5.</time_frame>
    <description>Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may have been represented in more than 1 category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 2</measure>
    <time_frame>Day 1 through Day 7 after vaccination 2 for Group 4</time_frame>
    <description>Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may have been represented in more than 1 category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 1</measure>
    <time_frame>Day 1 through Day 7 after vaccination 1 for Group 4 and after the single vaccination in Group 5.</time_frame>
    <description>Systemic events (any fever 38 degrees Celsius [C] or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives [urticaria], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 2</measure>
    <time_frame>Day 1 through Day 7 after vaccination 2 for Group 4</time_frame>
    <description>Systemic events (any fever 38 degrees C or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives [urticaria], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">373</enrollment>
  <condition>Pneumococcal Disease</condition>
  <condition>13-valent Pneumococcal Vaccine</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects 6 weeks to &lt;10 months of age with 0 prior dose of Prevnar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects &lt;12 months of age with 1 prior dose of Prevnar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects &lt;12 months of age with 2 prior doses of Prevnar.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects ≥12 months to &lt;2 years of age.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects ≥2 years to &lt;5 years of age</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)</description>
    <arm_group_label>Group1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)</description>
    <arm_group_label>Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )</description>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>13-valent Pneumococcal Conjugate Vaccine</intervention_name>
    <description>1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)</description>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female infants 6 weeks to &lt; 5years of age in good health, available for the
             entire study period and reachable by phone, parents able to complete all relevant
             study procedures.

          -  Infants who have received Prevnar are eligible to participate, but this is not
             required.

          -  Infants participating in the blood draws must live in a specific identified area
             (Yukon Kuskokwim Delta region)

        Exclusion Criteria:

          -  Contraindication to vaccination with pneumococcal vaccine or allergic reaction to any
             vaccines or vaccine related components, immune deficiency, bleeding disorder or major
             known congenital malformation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>42 Days</minimum_age>
    <maximum_age>5 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Akiak</city>
        <state>Alaska</state>
        <zip>99552</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Bethel</city>
        <state>Alaska</state>
        <zip>99559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chefornak</city>
        <state>Alaska</state>
        <zip>99561</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Chevak</city>
        <state>Alaska</state>
        <zip>99563</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Eek</city>
        <state>Alaska</state>
        <zip>99578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Emmonak</city>
        <state>Alaska</state>
        <zip>99581</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hooper Bay</city>
        <state>Alaska</state>
        <zip>99604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kasigluk</city>
        <state>Alaska</state>
        <zip>99609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kongiganak</city>
        <state>Alaska</state>
        <zip>99545</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kotlik</city>
        <state>Alaska</state>
        <zip>99620</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kwethluk</city>
        <state>Alaska</state>
        <zip>99621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kwigillingok</city>
        <state>Alaska</state>
        <zip>99622</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Mtn. Village</city>
        <state>Alaska</state>
        <zip>99632</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Napaskiak</city>
        <state>Alaska</state>
        <zip>99559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Newtok</city>
        <state>Alaska</state>
        <zip>99559</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nunapitchuk</city>
        <state>Alaska</state>
        <zip>99641</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Russian Mission</city>
        <state>Alaska</state>
        <zip>99657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Scammon Bay</city>
        <state>Alaska</state>
        <zip>99662</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toksook Bay</city>
        <state>Alaska</state>
        <zip>99637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tuluksak</city>
        <state>Alaska</state>
        <zip>99679</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Upper Kalskag</city>
        <state>Alaska</state>
        <zip>99607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=6096A1-3010&amp;StudyName=Study%20Evaluating%20the%20Impact%20of%20the%2013-valent%20Pneumococcal%20Conjugate%20Vaccine%20%2813vPnC%29%20in%20Alaskan%20Native%20Children.</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 27, 2008</study_first_submitted>
  <study_first_submitted_qc>August 28, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 29, 2008</study_first_posted>
  <results_first_submitted>September 9, 2011</results_first_submitted>
  <results_first_submitted_qc>January 5, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 10, 2012</results_first_posted>
  <last_update_submitted>March 13, 2012</last_update_submitted>
  <last_update_submitted_qc>March 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 15, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>13 valent Pneumococcal Conjugate Vaccine</keyword>
  <keyword>Antibody Response</keyword>
  <keyword>safety</keyword>
  <keyword>Alaskan Native Children</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumococcal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
    <mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Blood sample was optional for subjects living in the Bethel area. Active vaccination stopped when 13-valent pneumococcal conjugate vaccine (13vPnC) was commercially available in Alaska. Study ended after a 6-month follow-up for safety following the last vaccination.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
          <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
        </group>
        <group group_id="P2">
          <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
          <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
        </group>
        <group group_id="P3">
          <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
          <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
        </group>
        <group group_id="P4">
          <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
          <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
        </group>
        <group group_id="P5">
          <title>13vPnC Group 5 (1 Catch-Up Dose)</title>
          <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="67"/>
                <participants group_id="P5" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 1</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
                <participants group_id="P2" count="51"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="66"/>
                <participants group_id="P5" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 2</title>
              <participants_list>
                <participants group_id="P1" count="112"/>
                <participants group_id="P2" count="41"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="49"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Vaccinated Dose 3</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Toddler Dose</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="141"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="63"/>
                <participants group_id="P5" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Parent/Legal Guardian Request</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator Request</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
          <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
        </group>
        <group group_id="B2">
          <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
          <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
        </group>
        <group group_id="B3">
          <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
          <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
        </group>
        <group group_id="B4">
          <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
          <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
        </group>
        <group group_id="B5">
          <title>13vPnC Group 5 (1 Catch-Up Dose)</title>
          <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="151"/>
            <count group_id="B2" value="51"/>
            <count group_id="B3" value="25"/>
            <count group_id="B4" value="67"/>
            <count group_id="B5" value="79"/>
            <count group_id="B6" value="373"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.4" spread="0.6"/>
                    <measurement group_id="B2" value="4.4" spread="0.8"/>
                    <measurement group_id="B3" value="7.1" spread="1.6"/>
                    <measurement group_id="B4" value="15.2" spread="3.4"/>
                    <measurement group_id="B5" value="40.1" spread="11.1"/>
                    <measurement group_id="B6" value="12.9" spread="15.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="73"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="36"/>
                    <measurement group_id="B5" value="47"/>
                    <measurement group_id="B6" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="31"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 Micrograms Per Milliliter (Mcg/mL) 1 Month After the Infant Series</title>
        <description>Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
        <time_frame>28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.</time_frame>
        <population>Evaluable immunogenicity population: received treatments as randomized at all expected doses, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-Specific Pneumococcal Immunoglobulin G (IgG) Antibody Level ≥0.35 Micrograms Per Milliliter (Mcg/mL) 1 Month After the Infant Series</title>
          <description>Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population: received treatments as randomized at all expected doses, blood drawn within specified timeframes, at least 1 valid and determinate assay result for proposed analysis, and no major protocol violations. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Toddler Dose</title>
        <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
        <time_frame>28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Toddler Dose</title>
          <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Relevant Catch-Up Dose</title>
        <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
        <time_frame>28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
            <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 5 (1 Catch-Up Dose)</title>
            <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.35 Mcg/mL 1 Month After the Relevant Catch-Up Dose</title>
          <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Serum IgG Antibody Level ≥0.35 Mcg/mL Prior to Vaccination With 13vPnC (Groups 4 and 5 Only)</title>
        <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
        <time_frame>28 to 56 days before vaccination 2 for Group 4, and before the single vaccination in Group 5.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
            <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 5 (1 Catch-Up Dose)</title>
            <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serum IgG Antibody Level ≥0.35 Mcg/mL Prior to Vaccination With 13vPnC (Groups 4 and 5 Only)</title>
          <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="6.8" upper_limit="93.2"/>
                    <measurement group_id="O2" value="50.0" lower_limit="15.7" upper_limit="84.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="66.7" lower_limit="29.9" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.0" lower_limit="19.4" upper_limit="99.4"/>
                    <measurement group_id="O2" value="33.3" lower_limit="7.5" upper_limit="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O2" value="12.5" lower_limit="0.3" upper_limit="52.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O2" value="37.5" lower_limit="8.5" upper_limit="75.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="6.8" upper_limit="93.2"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O2" value="33.3" lower_limit="7.5" upper_limit="70.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Infant Series</title>
        <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
        <time_frame>28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Infant Series</title>
          <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="39.0" upper_limit="94.0"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O2" value="66.7" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O3" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" lower_limit="30.8" upper_limit="89.1"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="66.7" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.6" lower_limit="30.8" upper_limit="89.1"/>
                    <measurement group_id="O2" value="50.0" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.5" lower_limit="23.4" upper_limit="83.3"/>
                    <measurement group_id="O2" value="66.7" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81.8" lower_limit="48.2" upper_limit="97.7"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="39.0" upper_limit="94.0"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" lower_limit="39.0" upper_limit="94.0"/>
                    <measurement group_id="O2" value="50.0" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O3" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Toddler Dose</title>
        <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
        <time_frame>28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Toddler Dose</title>
          <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0" lower_limit="1.3" upper_limit="98.7"/>
                    <measurement group_id="O2" value="66.7" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Relevant Catch-up Dose</title>
        <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
        <time_frame>28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
            <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 5 (1 Catch-Up Dose)</title>
            <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥1.0 Mcg/mL 1 Month After the Relevant Catch-up Dose</title>
          <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥1.0 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="66.7" lower_limit="29.9" upper_limit="92.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="77.8" lower_limit="40.0" upper_limit="97.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 1</title>
        <description>Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may have been represented in more than 1 category.</description>
        <time_frame>Day 1 through Day 7 after vaccination 1 for Group 4 and after the single vaccination in Group 5.</time_frame>
        <population>Safety Population: all participants who received at least 1 dose of 13vPnC; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants with specific characteristic</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
            <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 5 (1 Catch-Up Dose)</title>
            <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 1</title>
          <description>Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may have been represented in more than 1 category.</description>
          <population>Safety Population: all participants who received at least 1 dose of 13vPnC; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants with specific characteristic</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=65,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.3"/>
                    <measurement group_id="O2" value="48.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=63,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=64,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.8"/>
                    <measurement group_id="O2" value="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=62,76)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=63,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2"/>
                    <measurement group_id="O2" value="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=63,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any (n=65,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=63,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.1"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=64,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.7"/>
                    <measurement group_id="O2" value="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=63,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 2</title>
        <description>Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may have been represented in more than 1 category.</description>
        <time_frame>Day 1 through Day 7 after vaccination 2 for Group 4</time_frame>
        <population>Safety Population; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants with specific characteristic</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
            <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Local Reactions: Catch-up Dose 2</title>
          <description>Local reactions were reported by the parent/legal guardian using a diary card. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters [cm] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (&gt; 7.0 cm). Participants may have been represented in more than 1 category.</description>
          <population>Safety Population; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants with specific characteristic</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Tenderness: Any (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tenderness: Significant (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Any (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Mild (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Moderate (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Swelling: Severe (n=47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Any (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Mild (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Moderate (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Redness: Severe (n=48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 1</title>
        <description>Systemic events (any fever 38 degrees Celsius [C] or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives [urticaria], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.</description>
        <time_frame>Day 1 through Day 7 after vaccination 1 for Group 4 and after the single vaccination in Group 5.</time_frame>
        <population>Safety Population; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants with specific characteristic</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
            <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 5 (1 Catch-Up Dose)</title>
            <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 1</title>
          <description>Systemic events (any fever 38 degrees Celsius [C] or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives [urticaria], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.</description>
          <population>Safety Population; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants with specific characteristic</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
                <count group_id="O2" value="77"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 degrees C but ≤39 degrees C (n=35,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                    <measurement group_id="O2" value="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 degrees C but ≤40 degrees C (n=29,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.7"/>
                    <measurement group_id="O2" value="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=28,40)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=66,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.8"/>
                    <measurement group_id="O2" value="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=66,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.0"/>
                    <measurement group_id="O2" value="41.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=66,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3"/>
                    <measurement group_id="O2" value="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=66,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hives (urticaria) (n=66,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0"/>
                    <measurement group_id="O2" value="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of medication to treat symptoms (n=65,77)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.8"/>
                    <measurement group_id="O2" value="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 2</title>
        <description>Systemic events (any fever 38 degrees C or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives [urticaria], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.</description>
        <time_frame>Day 1 through Day 7 after vaccination 2 for Group 4</time_frame>
        <population>Safety Population; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants with specific characteristic</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
            <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Reporting Pre-Specified Systemic Events: Catch-up Dose 2</title>
          <description>Systemic events (any fever 38 degrees C or higher, decreased appetite, irritability, increased sleep, decreased sleep, hives [urticaria], and use of antipyretic medication) were reported using a diary card. Participants may have been represented in more than 1 category.</description>
          <population>Safety Population; N=number of participants reporting yes for at least 1 day or no for all days; n=number of participants with specific characteristic</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fever ≥38 degrees C but ≤39 degrees C (n=26)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;39 degrees C but ≤40 degrees C (n=22)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fever &gt;40 degrees C (n=21)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased appetite (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irritability (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Increased sleep (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Decreased sleep (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hives (urticaria) (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Use of medication to treat symptoms (n=49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Number of Cases of Invasive Pneumococcal Disease (IPD) in Participants Less Than 5 Years of Age Due to Any Serotype Contained in 13vPnC</title>
        <description>In order to assess the impact of 13vPnC on the incidence of IPD in the Yukon Kuskokwim (YK) Delta region, the Centers for Disease Control and Prevention (CDC) Arctic Investigation Program (AIP) accessed IPD data through evaluation of ongoing statewide IPD surveillance in Alaska. The CDC’s AIP followed IPD (including serotype and vaccination history) to show whether identified cases of IPD received Prevnar, 13vPnC, or both. These data were combined with statewide data and used to identify the overall trend in IPD in the YK Delta region after introduction of 13vPnC.</description>
        <time_frame>Baseline to 6 months after last vaccination</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC (All Participants)</title>
            <description>All participants 6 weeks to &lt;5 years of age who received at least one single IM 0.5 mL dose of 13vPnC in either the infant series or the toddler dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Cases of Invasive Pneumococcal Disease (IPD) in Participants Less Than 5 Years of Age Due to Any Serotype Contained in 13vPnC</title>
          <description>In order to assess the impact of 13vPnC on the incidence of IPD in the Yukon Kuskokwim (YK) Delta region, the Centers for Disease Control and Prevention (CDC) Arctic Investigation Program (AIP) accessed IPD data through evaluation of ongoing statewide IPD surveillance in Alaska. The CDC’s AIP followed IPD (including serotype and vaccination history) to show whether identified cases of IPD received Prevnar, 13vPnC, or both. These data were combined with statewide data and used to identify the overall trend in IPD in the YK Delta region after introduction of 13vPnC.</description>
          <population>Safety Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="373"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Infant Series</title>
        <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
        <time_frame>28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-Specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Infant Series</title>
          <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="71.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Toddler Dose</title>
        <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
        <time_frame>28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Toddler Dose</title>
          <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Relevant Catch-up Dose</title>
        <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
        <time_frame>28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
            <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 5 (1 Catch-Up Dose)</title>
            <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Serotype-specific Pneumococcal IgG Antibody Level ≥0.15 Mcg/mL 1 Month After the Relevant Catch-up Dose</title>
          <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving predefined antibody threshold ≥0.15 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based upon the observed proportion of participants.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate IgG antibody concentration to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal IgG Antibodies 1 Month After the Infant Series</title>
        <description>Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.</description>
        <time_frame>28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate antibody concentration to the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Concentration (GMC) for Serotype-Specific Pneumococcal IgG Antibodies 1 Month After the Infant Series</title>
          <description>Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate antibody concentration to the specified serotype.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.64" lower_limit="1.55" upper_limit="4.49"/>
                    <measurement group_id="O2" value="2.11" lower_limit="0.93" upper_limit="4.80"/>
                    <measurement group_id="O3" value="4.27" lower_limit="0.49" upper_limit="37.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.74" lower_limit="1.23" upper_limit="6.12"/>
                    <measurement group_id="O2" value="2.59" lower_limit="0.55" upper_limit="12.26"/>
                    <measurement group_id="O3" value="28.60" lower_limit="0.12" upper_limit="7043.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.38" lower_limit="0.97" upper_limit="1.98"/>
                    <measurement group_id="O2" value="1.04" lower_limit="0.46" upper_limit="2.38"/>
                    <measurement group_id="O3" value="1.60" lower_limit="0.31" upper_limit="8.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" lower_limit="1.71" upper_limit="13.33"/>
                    <measurement group_id="O2" value="4.08" lower_limit="1.68" upper_limit="9.88"/>
                    <measurement group_id="O3" value="10.73" lower_limit="0.06" upper_limit="1894.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" lower_limit="1.04" upper_limit="3.21"/>
                    <measurement group_id="O2" value="1.66" lower_limit="0.92" upper_limit="2.98"/>
                    <measurement group_id="O3" value="2.99" lower_limit="0.40" upper_limit="22.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.55" lower_limit="2.10" upper_limit="6.01"/>
                    <measurement group_id="O2" value="1.61" lower_limit="0.65" upper_limit="4.01"/>
                    <measurement group_id="O3" value="2.37" lower_limit="1.43" upper_limit="3.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" lower_limit="0.79" upper_limit="3.01"/>
                    <measurement group_id="O2" value="1.03" lower_limit="0.35" upper_limit="3.04"/>
                    <measurement group_id="O3" value="3.37" lower_limit="1.18" upper_limit="9.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.33" lower_limit="1.68" upper_limit="6.62"/>
                    <measurement group_id="O2" value="3.02" lower_limit="1.06" upper_limit="8.60"/>
                    <measurement group_id="O3" value="2.87" lower_limit="0.30" upper_limit="27.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.79" lower_limit="0.51" upper_limit="1.22"/>
                    <measurement group_id="O2" value="1.61" lower_limit="0.62" upper_limit="4.16"/>
                    <measurement group_id="O3" value="5.07" lower_limit="1.53" upper_limit="16.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.89" lower_limit="1.57" upper_limit="5.31"/>
                    <measurement group_id="O2" value="1.93" lower_limit="1.14" upper_limit="3.26"/>
                    <measurement group_id="O3" value="1.75" lower_limit="0.25" upper_limit="12.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.19" lower_limit="0.93" upper_limit="5.16"/>
                    <measurement group_id="O2" value="2.48" lower_limit="0.91" upper_limit="6.78"/>
                    <measurement group_id="O3" value="5.41" lower_limit="0.01" upper_limit="2495.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" lower_limit="1.99" upper_limit="5.61"/>
                    <measurement group_id="O2" value="3.18" lower_limit="1.24" upper_limit="8.12"/>
                    <measurement group_id="O3" value="6.21" lower_limit="1.84" upper_limit="20.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.87" lower_limit="1.11" upper_limit="3.17"/>
                    <measurement group_id="O2" value="1.35" lower_limit="0.56" upper_limit="3.25"/>
                    <measurement group_id="O3" value="0.97" lower_limit="0.37" upper_limit="2.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>GMC for Serotype-Specific Pneumococcal IgG Antibodies 1 Month After the Toddler Dose</title>
        <description>Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.</description>
        <time_frame>28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, after vaccination 2 for Group 3.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate antibody concentration to the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>GMC for Serotype-Specific Pneumococcal IgG Antibodies 1 Month After the Toddler Dose</title>
          <description>Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate antibody concentration to the specified serotype.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.16" lower_limit="0.00" upper_limit="199911.7"/>
                    <measurement group_id="O2" value="2.55" lower_limit="1.44" upper_limit="4.53"/>
                    <measurement group_id="O3" value="1.76" lower_limit="0.00" upper_limit="4004.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.64" lower_limit="0.00">value=3.929*10^11</measurement>
                    <measurement group_id="O2" value="12.01" lower_limit="4.23" upper_limit="34.08"/>
                    <measurement group_id="O3" value="11.32" lower_limit="0.01" upper_limit="11544.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" lower_limit="0.01" upper_limit="373.79"/>
                    <measurement group_id="O2" value="2.20" lower_limit="1.30" upper_limit="3.73"/>
                    <measurement group_id="O3" value="1.30" lower_limit="0.00" upper_limit="2387.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.18" lower_limit="0.06" upper_limit="2411.14"/>
                    <measurement group_id="O2" value="11.42" lower_limit="5.90" upper_limit="22.12"/>
                    <measurement group_id="O3" value="8.54" lower_limit="0.19" upper_limit="377.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.35" lower_limit="0.00" upper_limit="1681.49"/>
                    <measurement group_id="O2" value="2.22" lower_limit="1.22" upper_limit="4.03"/>
                    <measurement group_id="O3" value="2.42" lower_limit="0.08" upper_limit="72.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.00" lower_limit="0.00" upper_limit="11762036"/>
                    <measurement group_id="O2" value="2.84" lower_limit="1.03" upper_limit="7.79"/>
                    <measurement group_id="O3" value="3.65" lower_limit="0.00" upper_limit="130178.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.79" lower_limit="0.00" upper_limit="66245120"/>
                    <measurement group_id="O2" value="2.35" lower_limit="0.88" upper_limit="6.27"/>
                    <measurement group_id="O3" value="3.96">n=2 for this serotype, and the value for both participants was 3.96, thus there was no variability so 95% CI could not be determined</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" lower_limit="0.00" upper_limit="9338.28"/>
                    <measurement group_id="O2" value="4.19" lower_limit="1.46" upper_limit="12.02"/>
                    <measurement group_id="O3" value="16.70" lower_limit="0.00" upper_limit="5685164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.73" lower_limit="0.00" upper_limit="276.18"/>
                    <measurement group_id="O2" value="1.32" lower_limit="0.63" upper_limit="2.78"/>
                    <measurement group_id="O3" value="1.63" lower_limit="1.19" upper_limit="2.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.69" lower_limit="0.00" upper_limit="36146.55"/>
                    <measurement group_id="O2" value="3.56" lower_limit="1.96" upper_limit="6.46"/>
                    <measurement group_id="O3" value="5.85" lower_limit="0.02" upper_limit="1606.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.14" lower_limit="0.00">value=6.518*10^11</measurement>
                    <measurement group_id="O2" value="7.79" lower_limit="3.00" upper_limit="20.21"/>
                    <measurement group_id="O3" value="3.24" lower_limit="0.01" upper_limit="1555.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.45" lower_limit="0.47" upper_limit="117.40"/>
                    <measurement group_id="O2" value="5.55" lower_limit="2.59" upper_limit="11.87"/>
                    <measurement group_id="O3" value="4.50" lower_limit="0.05" upper_limit="440.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.53" lower_limit="2.63" upper_limit="42.07"/>
                    <measurement group_id="O2" value="3.21" lower_limit="1.23" upper_limit="8.39"/>
                    <measurement group_id="O3" value="8.86" lower_limit="0.00" upper_limit="8014211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>GMC for Serotype-specific Pneumococcal IgG Antibodies 1 Month After the Relevant Catch-up Dose</title>
        <description>Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.</description>
        <time_frame>28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate antibody concentration to the specified serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
            <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 5 (1 Catch-Up Dose)</title>
            <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
          </group>
        </group_list>
        <measure>
          <title>GMC for Serotype-specific Pneumococcal IgG Antibodies 1 Month After the Relevant Catch-up Dose</title>
          <description>Antibody GMCs (mcg/mL) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) with 2-sided 95% CIs were evaluated. CIs are back transformations of confidence levels based on Student t distribution for mean logarithm of concentrations. GMCs were calculated using all participants with available data for specified blood draw.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate antibody concentration to the specified serotype.</population>
          <units>mcg/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.16" lower_limit="1.16" upper_limit="14.91"/>
                    <measurement group_id="O2" value="4.92" lower_limit="1.94" upper_limit="12.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.49" lower_limit="4.31" upper_limit="63.06"/>
                    <measurement group_id="O2" value="22.94" lower_limit="10.84" upper_limit="48.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.22" lower_limit="1.20" upper_limit="8.64"/>
                    <measurement group_id="O2" value="5.16" lower_limit="2.34" upper_limit="11.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.02" lower_limit="2.18" upper_limit="37.29"/>
                    <measurement group_id="O2" value="16.99" lower_limit="6.08" upper_limit="47.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.22" lower_limit="2.22" upper_limit="8.05"/>
                    <measurement group_id="O2" value="5.08" lower_limit="2.43" upper_limit="10.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.39" lower_limit="0.78" upper_limit="14.78"/>
                    <measurement group_id="O2" value="6.45" lower_limit="4.23" upper_limit="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.94" lower_limit="1.82" upper_limit="13.41"/>
                    <measurement group_id="O2" value="5.41" lower_limit="2.30" upper_limit="12.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.37" lower_limit="2.89" upper_limit="30.34"/>
                    <measurement group_id="O2" value="1.25" lower_limit="0.64" upper_limit="2.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.65" lower_limit="1.13" upper_limit="2.40"/>
                    <measurement group_id="O2" value="1.91" lower_limit="1.06" upper_limit="3.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.51" lower_limit="2.77" upper_limit="7.34"/>
                    <measurement group_id="O2" value="2.31" lower_limit="1.41" upper_limit="3.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.42" lower_limit="1.77" upper_limit="31.06"/>
                    <measurement group_id="O2" value="4.46" lower_limit="2.09" upper_limit="9.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.81" lower_limit="3.32" upper_limit="23.39"/>
                    <measurement group_id="O2" value="3.14" lower_limit="1.93" upper_limit="5.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.40" lower_limit="2.96" upper_limit="6.54"/>
                    <measurement group_id="O2" value="5.61" lower_limit="2.69" upper_limit="11.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥Lower Limit of Quantitation (LLOQ) Measured 1 Month After the Infant Series</title>
        <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5*LOD for analysis.</description>
        <time_frame>28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Opsonophagocytic Assay (OPA) Titers ≥Lower Limit of Quantitation (LLOQ) Measured 1 Month After the Infant Series</title>
          <description>Percentage of participants in 13vPnC Groups 1, 2, and 3 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5*LOD for analysis.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="75.0" lower_limit="19.4" upper_limit="99.4"/>
                    <measurement group_id="O3" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="66.4" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="6.7" upper_limit="65.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="70.8"/>
                    <measurement group_id="O3" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="75.0" lower_limit="19.4" upper_limit="99.4"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="59.0" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="50.0" lower_limit="6.8" upper_limit="93.2"/>
                    <measurement group_id="O3" value="0.0" lower_limit="0.0" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.9" lower_limit="51.8" upper_limit="99.7"/>
                    <measurement group_id="O2" value="66.7" lower_limit="9.4" upper_limit="99.2"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.0" lower_limit="26.2" upper_limit="87.8"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="60.2"/>
                    <measurement group_id="O3" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.9" lower_limit="58.7" upper_limit="99.8"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.0" lower_limit="34.8" upper_limit="93.3"/>
                    <measurement group_id="O2" value="60.0" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O3" value="33.3" lower_limit="0.8" upper_limit="90.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="55.5" upper_limit="99.7"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="69.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0" lower_limit="44.4" upper_limit="97.5"/>
                    <measurement group_id="O2" value="75.0" lower_limit="19.4" upper_limit="99.4"/>
                    <measurement group_id="O3" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving OPA Titers ≥LLOQ Measured 1 Month After the Toddler Dose</title>
        <description>Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5*LOD for analysis.</description>
        <time_frame>28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving OPA Titers ≥LLOQ Measured 1 Month After the Toddler Dose</title>
          <description>Percentage of participants in 13vPnC Groups 1, 2 and 3 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5*LOD for analysis.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="50.0" lower_limit="11.8" upper_limit="88.2"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="80.0" lower_limit="28.4" upper_limit="99.5"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                    <measurement group_id="O2" value="80.0" lower_limit="28.4" upper_limit="99.5"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="60.0" lower_limit="14.7" upper_limit="94.7"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="83.3" lower_limit="35.9" upper_limit="99.6"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="66.7" lower_limit="22.3" upper_limit="95.7"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                    <measurement group_id="O3" value="100.0" lower_limit="2.5" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants Achieving OPA Titers ≥LLOQ Measured 1 Month After the Relevant Catch-up Dose</title>
        <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5*LOD for analysis.</description>
        <time_frame>28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
            <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 5 (1 Catch-Up Dose)</title>
            <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving OPA Titers ≥LLOQ Measured 1 Month After the Relevant Catch-up Dose</title>
          <description>Percentage of participants in 13vPnC Groups 4 and 5 achieving OPA with 95% CI for serotypes 4, 6B, 9V, 14, 18C, 19F, 23F, 1, 3, 5, 6A, 7F, and 19A. Exact 2-sided CI based upon the observed proportion of participants. The LLOQ in titers for each serotype was: Pn001, 18; Pn003, 12; Pn004, 21; Pn005, 29; Pn06A, 37; Pn06B, 43, Pn7F, 210; Pn09V, 345; Pn014, 35; Pn18C, 31; Pn19A, 18; Pn19F, 48; and Pn23F, 13. Limit of detection (LOD) established as lowest titer possible in assay, which was 8. OPA titers below LLOQ set to 0.5*LOD for analysis.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="63.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="15.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="29.2" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="54.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="87.5" lower_limit="47.3" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="63.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="75.0" lower_limit="34.9" upper_limit="96.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="87.5" lower_limit="47.3" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="63.1" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="39.8" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="47.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pneumococcal OPA Geometric Mean Titers (GMTs) 1 Month After the Infant Series</title>
        <description>Antibody geometric mean titers as measured by OPA assay for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMTs were calculated using all participants with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA Geometric Mean Titers (GMTs) 1 Month After the Infant Series</title>
          <description>Antibody geometric mean titers as measured by OPA assay for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMTs were calculated using all participants with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123" lower_limit="38.4" upper_limit="390.6"/>
                    <measurement group_id="O2" value="116" lower_limit="3.1" upper_limit="4294.7"/>
                    <measurement group_id="O3" value="36" lower_limit="0.3" upper_limit="4185.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="3.1" upper_limit="123.1"/>
                    <measurement group_id="O2" value="4">Within group, confidence intervals for serotypes for which participants all have the same titer value were not computed since variability cannot be estimated.</measurement>
                    <measurement group_id="O3" value="120" lower_limit="0.1" upper_limit="199619.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="151" lower_limit="49.6" upper_limit="457.7"/>
                    <measurement group_id="O2" value="31" lower_limit="0.7" upper_limit="1348.9"/>
                    <measurement group_id="O3" value="4">Within group, confidence intervals for serotypes for which participants all have the same titer value were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299" lower_limit="79.5" upper_limit="1124.8"/>
                    <measurement group_id="O2" value="81" lower_limit="0.1" upper_limit="52488.1"/>
                    <measurement group_id="O3" value="566" lower_limit="182.6" upper_limit="1755.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41" lower_limit="9.2" upper_limit="183.5"/>
                    <measurement group_id="O2" value="4">Within group, confidence intervals for serotypes for which participants all have the same titer value were not computed since variability cannot be estimated.</measurement>
                    <measurement group_id="O3" value="7" lower_limit="0.5" upper_limit="109.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="28.9" upper_limit="117.7"/>
                    <measurement group_id="O2" value="82" lower_limit="21.7" upper_limit="311.6"/>
                    <measurement group_id="O3" value="206" lower_limit="66.1" upper_limit="639.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26" lower_limit="9.6" upper_limit="72.3"/>
                    <measurement group_id="O2" value="18" lower_limit="2.9" upper_limit="110.8"/>
                    <measurement group_id="O3" value="9" lower_limit="0.3" upper_limit="234.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="731" lower_limit="182.2" upper_limit="2933.6"/>
                    <measurement group_id="O2" value="1069" lower_limit="337.1" upper_limit="3390.4"/>
                    <measurement group_id="O3" value="984" lower_limit="179.7" upper_limit="5383.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1396" lower_limit="790.5" upper_limit="2467.0"/>
                    <measurement group_id="O2" value="1177" lower_limit="692.5" upper_limit="2001.6"/>
                    <measurement group_id="O3" value="3485" lower_limit="2308.5" upper_limit="5261.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1280" lower_limit="610.3" upper_limit="2683.5"/>
                    <measurement group_id="O2" value="1450" lower_limit="370.4" upper_limit="5675.6"/>
                    <measurement group_id="O3" value="1790" lower_limit="0.0" upper_limit="72147076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332" lower_limit="98.0" upper_limit="1124.2"/>
                    <measurement group_id="O2" value="71" lower_limit="3.3" upper_limit="1516.0"/>
                    <measurement group_id="O3" value="449" lower_limit="0.1" upper_limit="2059598"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="868" lower_limit="304.4" upper_limit="2475.0"/>
                    <measurement group_id="O2" value="452" lower_limit="67.7" upper_limit="3023.6"/>
                    <measurement group_id="O3" value="906" lower_limit="0.6" upper_limit="1340206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58" lower_limit="17.7" upper_limit="191.3"/>
                    <measurement group_id="O2" value="158" lower_limit="2.5" upper_limit="9872.6"/>
                    <measurement group_id="O3" value="380" lower_limit="0.0">value=1.3309*10^8</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pneumococcal OPA GMTs 1 Month After the Toddler Dose</title>
        <description>Antibody geometric mean titers as measured by OPA assay for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMTs were calculated using all subjects with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, after vaccination 2 for Group 3.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA GMTs 1 Month After the Toddler Dose</title>
          <description>Antibody geometric mean titers as measured by OPA assay for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A). GMTs were calculated using all subjects with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599" lower_limit="422.4" upper_limit="850.2"/>
                    <measurement group_id="O2" value="58" lower_limit="2.6" upper_limit="1317.2"/>
                    <measurement group_id="O3" value="220">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="428" lower_limit="68.2" upper_limit="2681.9"/>
                    <measurement group_id="O2" value="460" lower_limit="35.0" upper_limit="6035.8"/>
                    <measurement group_id="O3" value="2765">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="775" lower_limit="5.8" upper_limit="104290.7"/>
                    <measurement group_id="O2" value="551" lower_limit="73.6" upper_limit="4120.2"/>
                    <measurement group_id="O3" value="779">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3311">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                    <measurement group_id="O2" value="387" lower_limit="14.8" upper_limit="10145.6"/>
                    <measurement group_id="O3" value="4316">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46" lower_limit="0.1" upper_limit="14754.5"/>
                    <measurement group_id="O2" value="66" lower_limit="14.4" upper_limit="305.2"/>
                    <measurement group_id="O3" value="165">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159" lower_limit="0.2" upper_limit="141793.2"/>
                    <measurement group_id="O2" value="138" lower_limit="60.9" upper_limit="313.7"/>
                    <measurement group_id="O3" value="402">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87" lower_limit="0.8" upper_limit="9175.7"/>
                    <measurement group_id="O2" value="30" lower_limit="5.4" upper_limit="164.2"/>
                    <measurement group_id="O3" value="88">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4590" lower_limit="258.5" upper_limit="81484.1"/>
                    <measurement group_id="O2" value="1575" lower_limit="810.3" upper_limit="3061.7"/>
                    <measurement group_id="O3" value="6105">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1259" lower_limit="210.3" upper_limit="7542.2"/>
                    <measurement group_id="O2" value="140" lower_limit="22.7" upper_limit="860.3"/>
                    <measurement group_id="O3" value="427">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1565" lower_limit="0.0">value=2.4794*10^8</measurement>
                    <measurement group_id="O2" value="605" lower_limit="17.1" upper_limit="21473.7"/>
                    <measurement group_id="O3" value="12470">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="397" lower_limit="0.0">value=2.4862*10^8</measurement>
                    <measurement group_id="O2" value="73" lower_limit="2.5" upper_limit="2087.3"/>
                    <measurement group_id="O3" value="532">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="227" lower_limit="0.0">value=1.208*10^12</measurement>
                    <measurement group_id="O2" value="313" lower_limit="30.6" upper_limit="3195.2"/>
                    <measurement group_id="O3" value="1660">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3207" lower_limit="0.0">value=1.9613*10^9</measurement>
                    <measurement group_id="O2" value="1688" lower_limit="480.3" upper_limit="5929.3"/>
                    <measurement group_id="O3" value="6954">Within group, confidence intervals for serotypes with only 1 participant who had a determinate OPA antibody titer were not computed since variability cannot be estimated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Pneumococcal OPA GMTs 1 Month After the Relevant Catch-up Dose</title>
        <description>Antibody geometric mean titers as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMTs were calculated using all participants with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.</description>
        <time_frame>28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.</time_frame>
        <population>Evaluable immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
            <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 5 (1 Catch-Up Dose)</title>
            <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
          </group>
        </group_list>
        <measure>
          <title>Pneumococcal OPA GMTs 1 Month After the Relevant Catch-up Dose</title>
          <description>Antibody geometric mean titers as measured by OPA assay for 13 pneumococcal serotypes (serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F). GMTs were calculated using all participants with available data for the specified blood draw. CIs for the GMTs are back transformations of confidence levels based on the Student t distribution for the mean logarithm of the titers.</description>
          <population>Evaluable immunogenicity population. N=number of participants with a determinate OPA antibody titer to the given serotype.</population>
          <units>Titers</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Common serotypes - serotype 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="594" lower_limit="107.1" upper_limit="3295.5"/>
                    <measurement group_id="O2" value="1165" lower_limit="261.1" upper_limit="5197.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 6B</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7236" lower_limit="3423.7" upper_limit="15294.0"/>
                    <measurement group_id="O2" value="6795" lower_limit="795.9" upper_limit="58012.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 9V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2748" lower_limit="457.9" upper_limit="16485.4"/>
                    <measurement group_id="O2" value="2979" lower_limit="883.6" upper_limit="10040.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotypes - serotype 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1159" lower_limit="31.2" upper_limit="42979.5"/>
                    <measurement group_id="O2" value="1547" lower_limit="347.4" upper_limit="6892.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 18C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5910" lower_limit="1824.6" upper_limit="19141.1"/>
                    <measurement group_id="O2" value="1871" lower_limit="915.7" upper_limit="3824.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 19F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1584" lower_limit="463.4" upper_limit="5417.3"/>
                    <measurement group_id="O2" value="594" lower_limit="84.8" upper_limit="4164.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Common serotype - serotype 23F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2870" lower_limit="2572.2" upper_limit="3203.4"/>
                    <measurement group_id="O2" value="1240" lower_limit="423.0" upper_limit="3632.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="402" lower_limit="285.8" upper_limit="564.7"/>
                    <measurement group_id="O2" value="62" lower_limit="18.0" upper_limit="211.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="218" lower_limit="102.0" upper_limit="466.8"/>
                    <measurement group_id="O2" value="202" lower_limit="136.0" upper_limit="299.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 5</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128" lower_limit="15.9" upper_limit="1032.0"/>
                    <measurement group_id="O2" value="63" lower_limit="13.3" upper_limit="302.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 6A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9067" lower_limit="5187.0" upper_limit="15848.5"/>
                    <measurement group_id="O2" value="2292" lower_limit="231.2" upper_limit="22724.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 7F</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7776" lower_limit="3701.3" upper_limit="16335.8"/>
                    <measurement group_id="O2" value="6086" lower_limit="2680.9" upper_limit="13818.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional serotype - serotype 19A</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="815" lower_limit="549.9" upper_limit="1206.8"/>
                    <measurement group_id="O2" value="400" lower_limit="68.4" upper_limit="2344.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Infant Series</title>
        <time_frame>28 to 56 days after vaccination 3 for Group 1, after vaccination 2 for Group 2, and after vaccination 1 for Group 3.</time_frame>
        <population>Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Infant Series</title>
          <population>Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="3"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</measurement>
                    <measurement group_id="O2" value="NA">Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</measurement>
                    <measurement group_id="O3" value="NA">Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Toddler Dose</title>
        <time_frame>28 to 56 days after vaccination 4 for Group 1, after vaccination 3 for Group 2, and after vaccination 2 for Group 3.</time_frame>
        <population>Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 1 (3 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants 6 weeks to less than (&lt;) 10 months of age with 0 prior doses of Prevnar received 3 single intramuscular (IM) 0.5 milliliter (mL) doses of 13-valent pneumococcal conjugate vaccine (13vPnC) at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at greater than (&gt;) 12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 2 (2 Doses Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series), and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
          <group group_id="O3">
            <title>13vPnC Group 3 (1 Dose Infant Series and 1 Toddler Dose)</title>
            <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series) and a single IM 0.5 mL dose of 13vPnC at &gt;12 months of age (toddler dose), at least 60 days after last infant dose.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Toddler Dose</title>
          <population>Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</measurement>
                    <measurement group_id="O2" value="NA">Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</measurement>
                    <measurement group_id="O3" value="NA">Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Relevant Catch-up Dose</title>
        <time_frame>28 to 56 days after vaccination 2 for Group 4, and after the single vaccination in Group 5.</time_frame>
        <population>Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</population>
        <group_list>
          <group group_id="O1">
            <title>13vPnC Group 4 (2 Catch-Up Doses)</title>
            <description>Participants greater than or equal to (≥) 12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
          </group>
          <group group_id="O2">
            <title>13vPnC Group 5 (1 Catch-Up Dose)</title>
            <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
          </group>
        </group_list>
        <measure>
          <title>Correlation of OPA and IgG Values for Each 13vPnC Serotype 1 Month After the Relevant Catch-up Dose</title>
          <population>Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA">Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</measurement>
                    <measurement group_id="O2" value="NA">Correlative analysis output data are only available as figures and were not analyzed or presented statistically.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Randomization to 6 months after last vaccination</time_frame>
      <desc>The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>Group 1 (Infant Series)</title>
          <description>Participants 6 weeks to &lt;10 months of age with 0 prior doses of Prevnar received 3 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series).</description>
        </group>
        <group group_id="E2">
          <title>Group 2 (Infant Series)</title>
          <description>Participants &lt;12 months of age with 1 prior dose of Prevnar received 2 single IM 0.5 mL doses of 13vPnC at least 28 days apart (infant series)</description>
        </group>
        <group group_id="E3">
          <title>Group 3 (Infant Series)</title>
          <description>Participants &lt;12 months of age with 2 prior doses of Prevnar received a single IM 0.5 mL dose of 13vPnC (infant series)</description>
        </group>
        <group group_id="E4">
          <title>Group 1 (Toddler Dose)</title>
          <description>Participants &gt;12 months of age received a single IM 0.5 mL dose of 13vPnC at least 60 days after last infant dose (toddler dose)</description>
        </group>
        <group group_id="E5">
          <title>Group 2 (Toddler Dose)</title>
          <description>Participants &gt;12 months of age received a single IM 0.5 mL dose of 13vPnC at least 60 days after last infant dose (toddler dose)</description>
        </group>
        <group group_id="E6">
          <title>Group 3 (Toddler Dose)</title>
          <description>Participants &gt;12 months of age received a single IM 0.5 mL dose of 13vPnC at least 60 days after last infant dose (toddler dose)</description>
        </group>
        <group group_id="E7">
          <title>Group 4 (2 Catch-Up Doses)</title>
          <description>Participants ≥12 months to &lt;2 years of age received 2 single IM 0.5 mL doses of 13vPnC at least 60 days apart.</description>
        </group>
        <group group_id="E8">
          <title>Group 5 (1 Catch-Up Dose)</title>
          <description>Participants ≥2 years to &lt;5 years of age received a single IM 0.5 mL dose of 13vPnC.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Laryngomalacia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Respiratory syncytial virus bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Pneumonia respiratory syncytial viral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Cellulitis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Meningitis haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Septic arthritis haemophilus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Meningitis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Herpangina</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Febrile convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Bronchial hyperreactivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Apnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Injection site swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="151"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="51"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="66"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

